Undisclosed Scaffold Program
Spinal Cord Injury
About Innervace
Innervace is a private, pre-clinical stage biotech focused on a novel regenerative medicine platform for neurological conditions. Its core technology involves engineered biomaterial scaffolds intended to provide structural and biochemical support to facilitate neural tissue repair. Operating in the high-need but technically challenging neuroregeneration space, the company is likely in the early stages of validating its platform and advancing lead candidates. Its success hinges on demonstrating safety and functional efficacy in complex CNS disorders.
View full company profileAbout Innervace
Innervace is a private, pre-clinical stage biotech focused on a novel regenerative medicine platform for neurological conditions. Its core technology involves engineered biomaterial scaffolds intended to provide structural and biochemical support to facilitate neural tissue repair. Operating in the high-need but technically challenging neuroregeneration space, the company is likely in the early stages of validating its platform and advancing lead candidates. Its success hinges on demonstrating safety and functional efficacy in complex CNS disorders.
View full company profileTherapeutic Areas
Other Spinal Cord Injury Drugs
| Drug | Company | Phase |
|---|---|---|
| itNSCs | Stemedica Cell Technologies | Development |
| MAP4343 | Mapreg | Preclinical |
| Spinal Cord Injury Program | BioAxone Biosciences | Clinical |
| Q-Cells | Q Therapeutics | Research |
| APOSEC | Aposcience | Pre-clinical |
| NG004 | Neurimmune | Phase 1 |
| Perineline™ | NeuroSolv Therapeutics | Phase 1 |
| Nogo-A Receptor Blocking Antibody | NovaGo Therapeutics | Phase 1b |